Septimbe clinical trial

Maximum tolerated dose (MTD) of Septimeb drug; a Phase1 clinical trial

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT201108014076N3

Enrollment

Registered

2011-11-20

Start date

2011-08-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV AIDS. Infectiouse disease

Interventions

Four groups, each group consist of three participants enrolled the study. Each group received a constant dose of Septimeb for two weeks. Group1 took 5 mili liter, Group 2 took 6 ml, 7ml in the third a

Treatment - Drugs

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion critria: age between 18 to 50 years old and HIV positive stable patients. Exclusion criteria: evidence of underlying disease and unwillinig to participate in the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Possible clinical side effects. Timepoint: Daily. Method of measurement: Clinical examination by physician.	—

Secondary

Measure	Time frame
Possible para clinical side effects. Timepoint: At the begining, first week and the end of study. Method of measurement: Blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Ahmad Seyed Alinaghi

Iranian Research center for HIV/AIDS

s_a_alinaghi@yahoo.com+98 21 6694 7984

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026